奇峰國際(01228.HK)擬認購一內地化工企業新股 續停牌
奇峰國際(01228.HK)公布,全資附屬公奇峰國際能源與兩名獨立第三方訂立意向書,並繳付1.2億元作為認購按金,以注資及認購山東廣悅化工的新股,其主要於中國內地從事輕質化工及煉油業務。
公司亦已委任核數師對一家石化企業過去三年財務報表進行審計,及委任中國律師對其進行法律方面之盡職調查。由於認購事項須待相關訂約方進一步磋商後方可作實,故並不一定會進行,公司股東及有意投資者在買賣公司證券時務請審慎行事。
公司自2014年11月20日起停牌。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.